<DOC>
	<DOCNO>NCT02607865</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate efficacy long-term safety oral semaglutide versus sitagliptin subject type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Long-term Safety Oral Semaglutide Versus Sitagliptin Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Male female , age least 18 year time signing informed consent For Japan : Male female , age least 20 year time signing informed consent Diagnosed T2DM ( type 2 diabetes mellitus ) least 90 day prior day screen HbA1c ( glycosylated haemoglobin ) 7.010.5 % ( 5391 mmol/mol ) ( inclusive ) . Stable daily dose metformin ( equal 1500 mg maximum tolerate dose document subject medical record ) alone combination SU ( = half maximum approve dose accord local label maximum tolerate dose document subject medical record ) within 90 day prior day screen Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) .For certain specific country : Additional specific requirement apply Family personal history Multiple Endocrine Neoplasia Type 2 ( MEN 2 ) Medullary Thyroid Carcinoma ( MTC ) History pancreatitis ( acute chronic ) History major surgical procedure involve stomach potentially affect absorption trial product ( e.g . subtotal total gastrectomy , sleeve gastrectomy , gastric bypass surgery ) Any follow : myocardial infarction , stroke hospitalization unstable angina and/or transient ischaemic attack within past 180 day prior day screen Subjects presently classify New York Heart Association ( NYHA ) Class IV . Planned coronary , carotid peripheral artery revascularisation know day screen . Renal impairment define estimate Glomerular Filtration Rate ( eGFR ) 60 mL/min/1.73 m^2 per Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) History presence malignant neoplasm within last 5 year ( except basal squamous cell skin cancer insitu carcinoma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>